Sarepta therapeutics, inc. (SRPT)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Cash flows from operating activities:
Net loss

-17,492

-235,703

-126,326

-276,403

-76,643

-140,895

-76,393

-109,267

-35,363

-23,998

-47,734

-63,046

84,090

-88,452

-56,742

-62,301

-59,770

-64,681

-51,939

-41,851

-61,559

-44,416

-29,226

-33,874

-28,273

-62,067

-49,554

8,038

-17,704

-1,410

-4,020

1,279

1,833

Adjustments to reconcile net loss to cash flows from operating activities:
Gain from sale of Priority Review Voucher

108,069

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Conversion of interest accrued to common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

Acquired in-process research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

-

0

0

0

Gain from sale of Priority Review Voucher

-

-

-

-

-

-

-

-

-

0

0

0

125,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

6,529

8,206

8,277

9,185

4,879

3,527

3,593

2,873

2,252

2,124

2,559

1,772

1,637

1,664

1,074

1,476

1,397

1,364

1,312

1,291

1,280

1,158

1,049

960

523

435

375

362

353

537

273

251

239

Reduction in the carrying amounts of the right of use assets

2,153

-

-

-

1,491

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of investment discount

1,284

996

1,649

2,324

3,476

2,930

1,914

1,569

1,259

544

84

160

100

393

-867

152

242

-1,457

192

298

315

584

721

608

519

-

-

-

-

-

-

-

-

Non-cash interest expense

6,342

5,557

5,374

5,305

5,208

4,984

5,248

5,018

4,940

2,479

83

35

82

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on disposal of assets

-

-

-

-

-

-

-

-

-10

-

-188

-119

-485

-248

-21

-9

-15

-17

-48

-1

-131

-76

0

-46

-6

-175

-59

-58

-65

-29

-117

-18

-26

Realized gain on sale of available-for-sale securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

-

0

0

0

Write-down of available-for-sale securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

-

0

0

0

Impairment charge on real estate owned

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

109

0

0

Stock-based compensation

24,024

22,064

20,637

19,762

16,139

12,838

11,484

15,279

10,526

7,366

6,922

10,465

5,712

6,869

9,428

6,830

6,835

6,348

5,683

5,930

14,156

5,767

4,649

5,587

4,342

1,238

692

440

708

675

592

717

1,145

Other

1,381

-

-

-

-88

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Increase in warrant valuation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-4,256

3,784

3,251

-51,784

-42,716

13,488

-10,926

-58,601

7,052

11,253

7,274

Changes in operating assets and liabilities, net:
Net increase in accounts receivable

15,996

22,847

11,051

6,471

1,466

443

5,616

3,137

10,380

4,717

6,960

5,513

7,050

1,242

4

-8

13

-

-

-

-

-946

-1,864

-2,623

4,319

-

-

-

-

-

-

-

-

Net increase in inventory

1,789

5,019

9,791

16,102

15,022

9,629

11,690

4,751

15,770

18,912

22,939

11,309

17,632

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net increase in other assets

27,966

7,381

7,002

8,144

79,564

52,294

54,478

34,538

-4,672

8,035

-1,966

10,059

-774

809

7,809

-2,786

3,180

-5,286

-1,268

-1,282

-7,413

4,845

9,907

13,243

6,018

-

-

-

-

-

-

-

-

Net increase in deferred revenue

820,437

-

-

-

682

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net (decrease) increase in accounts payable, accrued expenses and other liabilities

-57,718

-

-

-

1,451

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net increase in accounts payable, accrued expenses, lease liabilities and other liabilities

-

-

-

-

-

58,578

14,069

12,811

4,704

13,166

8,096

-7,451

-886

10,012

-4,245

7,756

-6,214

21,424

-2,561

4,518

-5,084

15,269

-215

-5,995

1,704

3,702

-4,468

615

-1,567

1,671

-3,772

4,906

5,191

Net (increase) decrease in accounts receivable and other assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,425

-2,375

1,707

1,830

-293

-6,230

-3,640

11,226

Net cash provided by (used in) operating activities

627,790

-163,795

-67,431

-79,004

-146,233

-122,420

-113,318

-117,254

-35,668

-31,058

-57,903

-85,147

-57,888

-81,233

-60,615

-43,284

-60,688

-31,272

-46,314

-28,531

-43,348

-25,449

-35,321

-39,504

-28,265

-7,158

-7,805

-5,682

-9,049

-5,648

-7,523

-442

-10,066

Purchase of property and equipment

9,120

17,257

9,429

16,682

16,263

20,203

20,091

8,697

12,166

3,899

765

2,871

4,465

2,914

840

419

1,168

1,085

1,147

637

532

3,139

12,464

4,515

5,326

0

-35

134

9

205

297

449

227

Proceeds from sale of Priority Review Voucher, net of commission

108,069

-

-

-

-

-

-

-

-

0

0

0

125,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of intangible assets

-

-

-

-

-

555

1,077

883

673

624

6,990

356

1,245

432

325

358

410

450

342

249

391

319

434

334

294

423

116

245

253

579

23

416

109

Purchase of available-for-sale securities

365,437

209,407

252,937

236,807

494,481

520,216

355,564

204,309

91,514

-

-

-

-

-

-

-

-

-

-

-

-

2,179

45,573

49,947

176,669

-

-

-

-

-

-

-

-

Maturity and sale of available-for-sale securities

250,000

244,778

245,001

579,017

42,300

303,238

313,332

159,150

90,093

-

-

-

80,000

-1

11,389

79,712

21,000

44,085

43,204

53,900

44,750

-

-

-

-

-

-

-

-

-

-

-

-

Other

1,192

-

-

-

855

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

-

0

0

0

Sale of marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

-

0

0

0

Acquisition costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

-

0

0

0

Net cash (used in) provided by investing activities

-17,680

17,080

-17,959

152,373

135,231

-237,736

-63,400

-55,092

-14,260

-493,695

124,949

-20,054

209,985

-198,774

10,224

78,935

19,422

-69,819

31,019

3,383

43,827

46,677

-20,541

-2,877

-182,289

-423

-81

-379

-262

-784

-320

-865

-336

Cash flows from financing activities:
Proceeds from issuance of common stock to Roche

-

1

0

89

365,264

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options and purchase of stock under the Employee Stock Purchase Program

7,482

-

-

-

12,299

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Taxes paid related to net share settlement of equity awards

4,798

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of June 2015 and July 2017 Term Loan

-

-

-

-

-

-

-

-

-

-

-

-

2,500

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from revolving line of credit

-

-

-

-

-

18,150

44,368

77,119

96,235

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of revolving line of credit

-

-

-

-

-

17,323

44,978

73,511

100,142

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of mortgage loans and notes payable

-

-

-

-

-

0

0

0

1,265

-

-

-

43

-2,473

2,525

26

2,525

25

2,524

24

25

-

-

-

-

-

-

-

-

-

-

-

-

Buyback of common stock pursuant to rescission offering

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

Withdrawal of partnership net assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

Proceeds from convertible debt offering

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

Proceeds from exercise of stock options and purchase of stock under the Employee Stock Purchase Program

-

-

-

-

-

-

-

21,743

12,643

-

7,693

1,337

2,749

9,963

8,786

693

1,488

5,685

4,233

540

431

-

-

-

-

157,276

21,404

0

1

0

32

32,232

116

Proceeds from exercise of options and warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,713

-

-

-

-

-

-

-

-

Repayments of long-term debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

24

23

21

22

21

21

20

21

20

20

Net cash provided by financing activities

319,022

256,966

1,733

6,292

377,563

521,283

-23,955

25,351

7,471

506,813

382,237

-1,174

206

7,287

333,712

38,167

-1,037

125,576

1,576

20,250

406

24

5,407

96,034

2,690

157,255

21,382

-21

-20

-20

11

32,212

96

Increase in cash, cash equivalents and restricted cash

929,132

110,251

-83,657

79,661

366,561

161,127

-200,673

-146,995

-42,457

-17,940

449,283

-106,375

152,303

-272,720

283,321

73,818

-42,303

24,485

-13,719

-4,898

885

21,252

-50,455

53,653

-207,864

149,674

13,496

-6,082

-9,331

-6,452

-7,832

30,905

-10,306

Supplemental disclosure of cash flow information:
Cash paid during the period for interest

5,385

-

-

-

-

4,447

803

5,205

853

988

386

247

291

363

371

419

409

410

322

19

18

17

20

20

20

21

22

21

22

22

23

22

23

Supplemental schedule of non-cash investing activities and financing activities:
Issuance costs related to the Roche Collaboration in accrued expenses

4,285

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Manufacturing right of use asset additions

27,554

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Manufacturing lease liability additions

24,783

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Maturity of restricted investment

-

-

-

-

-

-

-

-

-

0

0

0

10,695

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Intangible assets included in accrued expenses

-

-

-

-

-

-

-60

92

202

-

-7

86

179

-67

971

67

192

230

-65

70

100

83

-13

0

200

-

-

-

-

-

-

-

-

Accrual for debt issuance costs related to the term loans

-

-

-

-

-

-

-

-

-

-

200

0

400

-

0

0

400

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Tenant improvement paid by Landlord

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

89

-528

593

-

-

-

-

-

-

-

-

Intangible assets and property and equipment included in accrued expenses

6,154

-936

-785

-206

3,108

2,906

2,226

-2,691

2,980

-

-

-

330

-

-

80

19

-

-

-

45

-888

743

-3,111

3,533

-

-

-

-

-

-

-

-

Short-term securities-available-for-sale received in connection with the private offering

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

Issuance of common stock in satisfaction of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

5,570

3,171

3,044

31,800

391

0

0

0

-1

0

644

Shares withheld for taxes

-

-

-

-

-

-

-

-

-

-

1,482

144

165

213

1,851

60

44

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Reclassification of long term investments to short term investments

-

-

-

-

-

0

0

0

9,980

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Capitalized interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

99

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of common stock for building purchase

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

-

0

0

0

Assumption of long-term debt for building purchase

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

-

0

0

0

Issuance of common stock to acquire assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

-

0

0

0

Assumption of liabilities to acquire assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

-

0

0

0

Roche
Proceeds from issuance of common stock to Roche

316,338

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-